BIOMAT Database Logo BIOMAT Database Logo

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. 1998

M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Service d'Hépatologie, INSERM U481, and Centre de Recherche Claude Bernard sur les Hépatites Virales, Hôpital Beaujon, Clichy, France.

OBJECTIVE The aim of this study was to determine the predictors for sustained response to alpha interferon therapy in a large population of patients with chronic hepatitis C, using multivariate analysis. METHODS Two hundred and ninety-six patients were included in four controlled trials of alpha interferon. Pretreatment serum HCV RNA levels were assessed by the branched DNA version 2.0 assay and HCV genotypes by the reverse hybridization assay (LiPA). RESULTS Sustained responses were observed in 37%, 14% and 6% of the patients with low, medium and high pretreatment serum HCV RNA levels, respectively (p<10(-4)). Sustained responses were observed in 5%, 4%, 32% and 27% of the patients with genotype 1a, 1b, 2a and 3a, respectively (p<10(-4)). The multivariate analysis showed that a non-transfusional source of HCV infection, low serum HCV RNA levels and HCV genotypes non-1 (2a or 3a) were independent factors associated with sustained response to interferon therapy. CONCLUSIONS Virological factors (low pretreatment serum HCV RNA level and HCV genotype non-1a and non-1b), when adjusted in a large population of patients, using improved technology, are the main independent predictors of sustained response to alpha interferon therapy.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic

Related Publications

M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C.
October 1995, Hepatology (Baltimore, Md.),
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha.
January 1995, Journal of viral hepatitis,
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Predictors of a favorable response to alpha interferon therapy for hepatitis C.
November 1999, Clinics in liver disease,
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
[Predictors and scoring system for sustained complete response to conventional interferon-alpha therapy on chronic hepatitis B].
October 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.
January 2009, BMC gastroenterology,
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Hepatitis C virus genotypes in chronic hepatitis and response to interferon-alpha therapy.
November 1993, The Journal of infectious diseases,
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to alpha-interferon.
May 2000, Journal of gastroenterology and hepatology,
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Virological patterns of hepatitis C virus in chronic hepatitis C with biochemical sustained response to interferon therapy.
May 1996, Hepatology (Baltimore, Md.),
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration.
September 1997, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
M Martinot-Peignoux, and N Boyer, and M Pouteau, and C Castelnau, and N Giuily, and V Duchatelle, and A Aupérin, and C Degott, and J P Benhamou, and S Erlinger, and P Marcellin
Histological evaluation of the response to interferon-alpha therapy in chronic hepatitis C.
January 1998, Scandinavian journal of gastroenterology. Supplement,
Copied contents to your clipboard!